🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Renaissance Technologies (RenTech)’s RCKT Holdings & Trades

First Buy
Q1 2018
Duration Held
31 Quarters
Largest Add
Q4 2025
+283,997 Shares
Current Position
637,174 Shares
$2.28 M Value

Renaissance Technologies (RenTech)'s RCKT Position Overview

Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 637,174 shares of Rocket Pharmaceuticals, Inc. (RCKT) worth $2.28 M, representing 0.00% of the portfolio. First purchased in 2018-Q1, this long-term strategic position has been held for 31 quarters.

Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in RCKT, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2025, adding 283,997 shares. Largest reduction occurred in Q3 2025, reducing 324,197 shares.

Analysis based on 13F filings available since 2013 Q2

Renaissance Technologies (RenTech)'s Rocket Pharmaceuticals (RCKT) Holding Value Over Time

Track share changes against reported price movement

Quarterly Rocket Pharmaceuticals (RCKT) Trades by Renaissance Technologies (RenTech)

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q1 2026 +216,000 Add 51.29% 637,174 $3.58
Q4 2025 +283,997 Add 207.03% 421,174 $3.51
Q3 2025 -324,197 Reduce 70.27% 137,177 $3.26
Q2 2025 +122,900 Add 36.31% 461,374 $2.45
Q1 2025 +119,955 Add 54.89% 338,474 $6.67
Q4 2024 +218,519 New Buy 218,519 $12.57
Q3 2024 -99,574 Sold Out 0 $0.00
Q2 2024 +99,574 New Buy 99,574 $21.53
Q1 2024 -62,674 Sold Out 0 $0.00
Q4 2023 -130,800 Reduce 67.61% 62,674 $29.96
Q3 2023 +164,600 Add 570.06% 193,474 $20.49
Q2 2023 -84,500 Reduce 74.53% 28,874 $0.02
Q1 2023 -45,426 Reduce 28.61% 113,374 $0.02
Q4 2022 -321,000 Reduce 66.90% 158,800 $0.02
Q3 2022 +45,900 Add 10.58% 479,800 $15.96
Q2 2022 +277,400 Add 177.25% 433,900 $13.76
Q1 2022 +4,701 Add 3.10% 156,500 $15.86
Q4 2021 +36,306 Add 31.44% 151,799 $21.83
Q3 2021 +95,393 Add 474.59% 115,493 $29.89
Q2 2021 -35,490 Reduce 63.84% 20,100 $44.28
Q1 2021 +55,590 New Buy 55,590 $44.38
Q2 2020 -93,600 Sold Out 0 $0.00
Q1 2020 +93,600 New Buy 93,600 $13.95
Q4 2019 -27,900 Sold Out 0 $0.00
Q3 2019 +27,900 New Buy 27,900 $11.65
Q2 2019 -17,301 Sold Out 0 $0.00
Q1 2019 -18,517 Reduce 51.70% 17,301 $17.51
Q4 2018 -31,007 Reduce 46.40% 35,818 $14.82
Q3 2018 -196,820 Reduce 74.65% 66,825 $24.62
Q2 2018 +95,970 Add 57.24% 263,645 $19.63
Q1 2018 +167,675 New Buy 167,675 $18.75

Renaissance Technologies (RenTech)'s Rocket Pharmaceuticals Investment FAQs

Renaissance Technologies (RenTech) first purchased Rocket Pharmaceuticals, Inc. (RCKT) in Q1 2018, acquiring 167,675 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Renaissance Technologies (RenTech) has held Rocket Pharmaceuticals, Inc. (RCKT) for 31 quarters since Q1 2018.

Renaissance Technologies (RenTech)'s largest addition to Rocket Pharmaceuticals, Inc. (RCKT) was in Q4 2025, adding 421,174 shares worth $1.48 M.

According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 637,174 shares of Rocket Pharmaceuticals, Inc. (RCKT), valued at approximately $2.28 M.

As of the Q1 2026 filing, Rocket Pharmaceuticals, Inc. (RCKT) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.

Renaissance Technologies (RenTech)'s peak holding in Rocket Pharmaceuticals, Inc. (RCKT) was 637,174 shares, as reported at the end of Q1 2026.